USP 800 Cleanroom Requirements: Negative-Pressure Hazardous Drug Compounding Rooms

USP General Chapter <800>, "Hazardous Drugs — Handling in Healthcare Settings," sets facility engineering-control requirements for any space where a healthcare setting compounds a drug on the NIOSH List of Hazardous Drugs in Healthcare Settings. It became official on December 1, 2019, and its facility requirements are the reason a hospital or health-system compounding pharmacy that handles hazardous drugs — chemotherapy agents, and a number of other cytotoxic, teratogenic, or reproductively toxic medications — cannot simply compound them in an ordinary USP <797> sterile-compounding room. This guide covers what <800> actually requires of the room itself: pressure, air changes, ISO classification, venting, and the specific engineering-control categories the chapter defines, plus how it interacts with USP <797> and state-level enforcement.

Who this applies to

USP <800> applies to any entity that stores, compounds, or otherwise handles hazardous drugs as defined by NIOSH — hospital pharmacies, outpatient infusion centers, veterinary compounding operations, and investigational-drug services compounding hazardous investigational agents all fall in scope. It does not apply to a facility that only administers a hazardous drug from a manufacturer-prepared, ready-to-use dose without further manipulation, and non-sterile HD manipulation (counting/repackaging intact tablets, for example) has narrower requirements than sterile compounding. See Research Pharmacy: How Sites Set Up, Staff, and Run an Investigational Drug Service and Investigational Drug Service (IDS): Regulatory Role, Staffing, and Workflow for how this fits into a clinical-trial pharmacy’s broader compliance picture, and Chemotherapy Waste Disposal: RCRA Rules, Trace vs. Bulk Waste, and USP 800 for what happens to hazardous drug materials once compounding is finished.

The core engineering-control vocabulary

USP <800> defines the room and the equipment inside it as two separate, layered controls. Getting the terminology right matters because inspectors and accreditors check each layer independently.

• C-PEC (Containment Primary Engineering Control) — the device the compounder works directly in: a Class II biological safety cabinet (BSC) or compounding aseptic containment isolator (CACI) for sterile hazardous drug (HD) compounding, or a Class I BSC or containment ventilated enclosure (CVE) for non-sterile HD compounding. The C-PEC is what protects the compounder and the drug preparation from each other.
• C-SEC (Containment Secondary Engineering Control) — the room housing the C-PEC. This is the "cleanroom" in the ordinary sense of the term: a physically enclosed space with controlled air pressure, air change rate, and (for sterile compounding) ISO-classified air.
• C-SCA (Containment Segregated Compounding Area) — a permitted alternative to a full ante-room-plus-buffer-room C-SEC suite for low- and medium-risk sterile HD compounding, provided the C-PEC used is a CACI that maintains ISO Class 5 conditions during dynamic operating conditions at the compounding area. A C-SCA does not itself need to be ISO-classified room air, and unlike a full buffer/ante suite it can be a designated area rather than a permanent fixed-wall room — but it still has to meet the same pressure, venting, and air-change requirements described below.

Room-level requirements for sterile HD compounding

For sterile hazardous drug compounding using the full buffer-room-plus-anteroom model, USP <800> requires:

• Negative pressure of 0.01 to 0.03 inches of water column relative to all adjacent unclassified or lower-hazard spaces, continuously monitored and documented — the opposite pressure relationship from a standard non-hazardous USP <797> sterile compounding suite, which is kept positive to keep contaminants out. Here the goal is reversed: keep hazardous drug particulate from migrating out into occupied space.
• A minimum of 12 air changes per hour (ACPH) in the negative-pressure room.
• ISO Class 7 air classification (per ISO 14644-1) for both the buffer room and the anteroom, achieved and maintained by HEPA-filtered supply air. See Cleanroom Classifications: ISO 14644-1 and the FED-STD-209E Equivalents for what an ISO class actually specifies, and HEPA Filter Certification for Cleanrooms and Controlled Environments for how that filtration is tested and certified.
• External venting — the C-SEC must be exhausted to the outside, not simply recirculated through HEPA filtration back into the building, and the C-PEC inside it must also be externally vented.
• Physically separate from non-hazardous drug compounding areas — a facility cannot compound hazardous and non-hazardous sterile preparations in the same room.

These requirements sit on top of, not instead of, the general sterile-compounding facility requirements set out in USP <797> (see Cleanroom Checklist: Facility Compliance & Qualification for the shared ISO-classification and requalification framework both chapters rely on) — a hazardous drug compounding room has to satisfy both chapters simultaneously.

Non-sterile HD compounding requirements

Non-sterile hazardous drug compounding (crushing tablets for a compounded capsule, for example) does not require ISO-classified room air, but it still requires a C-PEC (typically a Class I BSC or CVE) that is externally vented, in a room that is negative-pressure relative to adjacent areas with a minimum of 12 ACPH. The room does not need the anteroom/buffer-room ISO-7 configuration that sterile HD compounding requires.

Surfaces, fixtures, and design details inspectors check

Beyond pressure and air changes, USP <800> and standard cleanroom design practice expect a facility to be able to demonstrate:

• Floors, walls, and ceilings finished in seamless, non-porous, low-permeability materials with coved (not square) floor-to-wall junctions, so surfaces can be effectively decontaminated and there is nowhere for hazardous drug residue to collect.
• No unsealed penetrations (electrical outlets, sprinkler heads, light fixtures) that would compromise pressure differential or provide a residue trap.
• A sink for hand hygiene located in the anteroom, not the buffer room, so hazardous drug contamination isn’t carried to a hand-washing point inside the negative-pressure zone.
• Eyewash and emergency shower access appropriate to the hazard — the general facility standard for this is ANSI Z358.1; see Laboratory Environmental Monitoring: Systems, Standards, and Setup for how pressure, ACPH, and temperature/humidity are continuously logged and alarmed in a controlled space like this one.
• Written, validated cleaning and deactivation procedures specific to hazardous drug residue, distinct from routine cleanroom cleaning — USP <800> requires deactivating, decontaminating, and cleaning in that specific sequence.

Qualification and ongoing monitoring

A new or renovated HD compounding room needs certification before use and requalification on a defined interval (commonly every six months, consistent with USP <797> sterile-compounding room requalification, though a facility’s own SOP and applicable state board requirements govern the exact interval). Certification records should independently document: non-viable particle counts against the ISO class, HEPA filter integrity (leak) testing, airflow velocity or ACPH, and pressure differential — the same four categories a general facility uses to requalify any classified cleanroom. See Cleanroom Checklist: Facility Compliance & Qualification for the full six-category requalification framework and how it applies across cleanroom types generally, and Laminar Flow Hood Certification: IEST-RP-CC002 Testing Explained for C-PEC-level (cabinet/hood) certification specifically, as distinct from room-level certification.

Is USP <800> actually enforceable?

USP <800> is numbered above <1000> in the USP–NF numbering convention, which under USP’s own General Notices means it is informational rather than automatically mandatorily enforceable on its own. In practice this distinction has narrowed sharply: USP <797> (sterile compounding, a mandatorily enforceable chapter numbered below <1000>) was revised effective November 1, 2023 to explicitly incorporate hazardous-drug handling requirements by cross-reference to <800>, so any facility performing sterile HD compounding is bound by <800>’s facility requirements as a practical matter of <797> compliance. Separately, most state boards of pharmacy have adopted USP <800> directly into their own compounding regulations regardless of USP’s internal enforceability framework, and it is a standard element of Joint Commission and other accreditation surveys for organizations that compound hazardous drugs. A compounding pharmacy should treat <800> as a compliance requirement, not an optional best-practice reference, and confirm the current status of both the USP–NF text and the applicable state board regulation before finalizing a facility design — these are periodically revised.

Frequently asked questions

What’s the difference between USP <797> and USP <800>?

USP <797> governs sterile compounding generally — contamination control to protect the patient and the preparation. USP <800> governs hazardous drug handling specifically — controls to protect the personnel and environment from the drug. A room compounding sterile hazardous drugs has to meet both simultaneously; a room compounding non-hazardous sterile drugs only needs to meet <797>.

Does a C-SCA need to be its own permanent room?

No. A containment segregated compounding area (C-SCA) is USP <800>’s allowance for low- and medium-risk sterile HD compounding to be done in a designated, non-ISO-classified area rather than a full fixed-wall ante/buffer suite, provided a CACI is used as the C-PEC and the area still meets the negative-pressure, 12 ACPH, and external-venting requirements. It is a lower-cost path for lower-volume compounding, not an exemption from the underlying engineering controls.

Why is the hazardous drug room negative-pressure when other sterile compounding rooms are positive-pressure?

A standard non-hazardous sterile compounding room is kept positive-pressure to keep outside contaminants (and their microbial load) from migrating in and contaminating the preparation. A hazardous drug room reverses that logic: the primary risk is hazardous drug particulate migrating out into occupied space and exposing personnel, so the room is kept negative relative to its surroundings, with the exhaust vented outside the building rather than recirculated.

Which drugs actually trigger USP <800> requirements?

Any drug on the NIOSH List of Hazardous Drugs in Healthcare Settings, which NIOSH updates periodically and groups into antineoplastic, non-antineoplastic, and reproductive-hazard categories. A facility’s HD list should be checked against the current NIOSH list rather than assumed static, since drugs are added and removed between updates.

This page describes the general engineering-control framework in USP General Chapter <800>. It is not a substitute for the current official USP–NF chapter text, your state board of pharmacy’s compounding regulations, or a qualified facility-design consultant when specifying or certifying an actual hazardous drug compounding room.